Clinical Trials Logo

Venous Thrombosis clinical trials

View clinical trials related to Venous Thrombosis.

Filter by:

NCT ID: NCT06385353 Not yet recruiting - Clinical trials for Postthrombotic Syndrome

DVT Burden and the Risk of Post-thrombotic Syndrome

DVT-Burden
Start date: June 2024
Phase: N/A
Study type: Interventional

Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis (DVT), with major consequences for patient quality of life and cost of management. Identifying patients at high risk of developing PTS could be useful for its prevention and may lead to more appropriate therapeutic strategies to reduce its incidence and severity. Prognostic tools for predicting risk are very useful for choosing the optimum treatment and improving patient management and are a preliminary step before developing predictive models useful for determining sensitivity to treatment. At present, although several prognostic markers and models have been proposed, it is still difficult to predict who will develop a PTS or a moderate to severe PTS. The development of PTS is multifactorial and depends largely on the extent and severity of venous obstruction which supports the theory of thrombosis burden (DVT-Burden) as a potential prognostic marker for PTS. It therefore seems important to study the association between thrombosis burden and the occurrence of PTS. The Venous Volumetric Index or VVI (Ouriel 1999) will be used for quantifying DVT-Burden. The VVI was constructed by calculating the volume from the diameter and length of 14 venous segments from the calf veins to the inferior vena cava. The VVI has been validated for its ability to discriminate between symptomatic and asymptomatic DVT and has shown superior performance to other methods for quantifying DVT. This study aim to assess the performance of baseline DVT-burden estimated by the VVI score on ultrasound for predicting the occurrence and the severity of PTS as assessed by the Villalta scale at 6 months.

NCT ID: NCT06370702 Recruiting - Clinical trials for Deep Vein Thrombosis

Evaluating the Use of Grip Exercises to Decrease Deep Vein Thrombosis in Adult Patients With PICC Lines

Start date: October 6, 2023
Phase: N/A
Study type: Interventional

Patients who have a peripherally-inserted central catheter (PICC) placed are at a risk of developing a deep vein thrombosis (DVT). At TriHealth, approximately 2-4 patients per month who have a PICC placed experience a subsequent DVT. One innovative way to possibly mitigate the risk of DVTs is hand grip exercises. The current study will be the first study to evaluate hand grip exercises for the prevention of DVTs in adult patients hospitalized in the United States.

NCT ID: NCT06365528 Not yet recruiting - Clinical trials for Deep Vein Thrombosis

Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes

Start date: May 2, 2024
Phase: N/A
Study type: Interventional

The aim of this multicenter randomized clinical trial is to compare the tunneling technique of PICC insertion with the non-tunneled insertion technique in the incidence of the combined or isolated outcome of catheter-related bloodstream primary infection, thrombosis, obstruction, and accidental dislodgement in the adult population within a period of up to 30 days.

NCT ID: NCT06349291 Not yet recruiting - Thrombosis, Venous Clinical Trials

Venous Thrombosis After Removal of Central Venous Catheter

Start date: August 1, 2024
Phase:
Study type: Observational

Insertion of intravenous catheter is a very common operation in patients in the general intensive care unit. These catheters are used for a variety of purposes - administration of inotropics/pressors, intravenous nutrition, concentrated electrolytes and performing dialysis.There are several known complications of central venous catheter insertion, such as thrombosis and pulmonary embolism. In a literature review, there are no clear data regarding the rate of intravenous thrombosis in patients after removal of a central venous catheter. These findings are often discovered randomly, when the patient undergoes imaging for a different indication. There is no recommendation for an active search for intravenous thrombi at the catheter insertion sites in these patients, and it is not entirely clear whether it is mandatory to administer anticoagulant treatment in these patients if thrombi are randomly discovered at the catheter insertion sites. In this study, we aim to check the proportion of patients who developed thrombosis at the central catheter insertion sites after its removal, to check whether there are catheter insertion sites that are at a higher risk of developing thrombosis than other sites, and to check whether there are predictive characteristics for the development of this type of thrombosis.

NCT ID: NCT06341010 Not yet recruiting - Clinical trials for Iliofemoral Deep Vein Thrombosis

The Role of Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis

Start date: May 1, 2024
Phase:
Study type: Observational

The aim of this study is to evaluate the efficacy and safety of rheolytic thrombectomy in restoring venous patency DVT, periprocedural complications and development of PTS after tratment of iliofemoral DVT.

NCT ID: NCT06340763 Not yet recruiting - Clinical trials for Peripheral Venous Thrombosis

JETi Hong Kong Post Market Study (PMS)

Start date: May 2024
Phase:
Study type: Observational

The JETi Hong Kong PMS is a prospective, single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the JETi System for the treatment of acute and subacute thrombosis in the lower extremity peripheral vasculature. This is a post-market study that will register approximately 20 subjects at approximately 5 centers in Hong Kong. Subjects participating in this study will be followed for up to 30 days after the JETi procedure.

NCT ID: NCT06319131 Not yet recruiting - Clinical trials for Portal Vein Thrombosis

Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the comparative effectiveness of nadroparin versus transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory asymptomatic portal vein thrombosis using a design of a multicenter, randomized controlled trial

NCT ID: NCT06318754 Not yet recruiting - Thrombosis Clinical Trials

Large-Bore Mechanic Thrombectomy for the Treatment of Symptomatic Portomesenteric Vein Thrombosis

Start date: June 2024
Phase:
Study type: Observational

A single site study evaluating the safety, feasibility, and effectiveness of percutaneous large-bore mechanical thrombectomy using the Inari Triever Aspiration Catheter for the treatment of portomesenteric vein thrombosis (PMVT).

NCT ID: NCT06288906 Not yet recruiting - Thrombosis, Venous Clinical Trials

Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems

ASTER
Start date: March 30, 2024
Phase:
Study type: Observational

This is a physician-initiated, observational, monocentric, retrospective and prospective Study. The study is intended to assess the feasibility of mechanical thrombectomy of caval and iliofemoral veins according to normal clinical practice in adult patients with symptomatic acute or subacute ileofemoral or caval deep vein thrombosis objectively diagnosed with CT scan imaging.

NCT ID: NCT06266585 Completed - Clinical trials for Cerebral Venous Thrombosis

Clinical Deterioration in Cerebral Venous Thrombosis: A Predictive Study

Start date: January 1, 2023
Phase:
Study type: Observational

The objective of this retrospective, prospective, multicenter cohort study is to determine the risk factors for deterioration of CVT patients after admission and establish a scoring model for risk stratification of patients. This study included two stages, the first stage was to enroll CVT patients from a single center from 2017 to 2022 for modeling, and the second stage was to enroll CVT patients from three centers in 2023 for external validation